Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2Phase 1 2Phase EARLY_PHASE1 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 1Genitourinary 1

Conditions

Prostatic Neoplasms 1Oropharyngeal Neoplasms 1

Interventions

Cisplatin 1519Carboplatin 1420Cyclophosphamide 1360Gemcitabine 1235Bevacizumab 1226Paclitaxel 1211Radiotherapy 1176Docetaxel 1080pembrolizumab 1028Oxaliplatin 936Capecitabine 900Fluorouracil 833Rituximab 729Doxorubicin 683Nivolumab 679Dexamethasone 666Etoposide 660Irinotecan 622Leucovorin 575Pemetrexed 510Drug Therapy 493Cetuximab 483Trastuzumab 469Cytarabine 466Magnetic Resonance Spectroscopy 458Filgrastim 446Prednisone 432Lenalidomide 409Specimen Handling 408Temozolomide 400

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Vaccines, DNA × Clear all
NCT05799144 2025-10-22

pBI-11 & TA-HPV (With Pembrolizumab as Treatment for Patients w/Advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal Cancer

Vanderbilt-Ingram Cancer Center

Phase 2 Recruiting
54 enrolled
Head & Neck

Oropharyngeal Neoplasms

NCT01706458 2021-06-18

Provenge With or Without pTVG-HP DNA Booster Vaccine in Prostate Cancer

University of Wisconsin, Madison

Phase 2 Completed
18 enrolled 16 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡